ResMed, Verily join forces on sleep apnea

 - 
Wednesday, July 11, 2018

SAN DIEGO – ResMed has partnered with Verily on a new joint venture to study the health and financial impacts of undiagnosed and untreated sleep apnea, the companies announced today. They will also develop software solutions to enable healthcare providers to more efficiently diagnose, treat and manage individuals with sleep apnea and other breathing related sleep disorders. “The vast majority of people with sleep apnea don’t realize they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D. “The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life.” Launched in 2015, Verily is a subsidiary of Alphabet that develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. Its mission: “Make the world’s health data useful so that people enjoy healthier lives.”